• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Coherus Bio (NQ: CHRS )

    1.670 -0.070 (-4.02%)
    Streaming Delayed Price Updated: 10:23 AM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 270,298
    Open 1.720
    Bid (Size) 1.660 (24)
    Ask (Size) 1.670 (10)
    Prev. Close 1.740
    Today's Range 1.640 - 1.720
    52wk Range 1.250 - 5.465
    Shares Outstanding 114,725,740
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
    Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to... 
    Via Talk Markets
    Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
    – Transaction aligns with Coherus’ strategic focus on oncology – 
    From Coherus BioSciences, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -46.82%
    -46.82%
    1 Month
    +1.83%
    +1.83%
    3 Month
    -22.33%
    -22.33%
    6 Month
    -32.11%
    -32.11%
    1 Year
    -61.96%
    -61.96%

    More News

    Read More
    Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Recap: Coherus BioSciences Q4 Earnings
    Via Benzinga
    Earnings Preview For Coherus BioSciences
    Via Benzinga
    Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    CHRS Stock Earnings: Coherus BioSciences Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Why Coherus Biosciences Stock Tumbled on Thursday
    Via The Motley Fool
    Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Completes Divestiture of Ophthalmology Franchise
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Earnings Scheduled For March 13, 2024
    Via Benzinga
    Coherus BioSciences Announces New Employment Inducement Grants
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Why Coherus BioSciences Stock Jumped Today
    Via The Motley Fool
    Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Why Coherus BioSciences Stock Is Sinking Today
    Via The Motley Fool
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.